AbbVie partners with Iambic to deploy its AI molecular superintelligence platform, while Telix Pharmaceuticals agrees to acquire radioisotope leader ITM.
|Articles|June 1, 2008
- Pharmaceutical Executive-06-01-2008
- Volume 0
- Issue 0
Safi Bahcall, Synta Pharmaceuticals
S
Advertisement
Safi Bahcall
CEO, Synta Pharmaceuticals
FORMER PROFESSION: Astrophysicist (like both his parents)
GOAL: For Synta to be the next Celgene or Genentech
Until 2003, everything was abstract. Papers, ideas, concepts, and theories. And then I went to Boston to meet the first patient who was getting dosed with our first drug for the first time. The patient was a young guy, with an IV bag going into his arm, who had cancer. It was our drug in that bag, and he was looking at me, hoping that our drug would make him not die. The doctor and nurse just left, so I sat down in the chair next to his bed, and we started talking—about travelling, restaurants, biking. And all the stuff that I've done—the stock options, business plans, whatever—they all just melted way. Everything in the past just faded. And I realized that everything that counted, it was there. It's those moments that reframe everything and let you realize how important it is to do what we are doing."
Safi Bahcall
Articles in this issue
over 18 years ago
Mary Szela, Abbottover 18 years ago
Mightier Than the Swordover 18 years ago
Keeshia Muhammad, Teva Specialty Pharmaceuticalsover 18 years ago
Eric Floyd, Cephalonover 18 years ago
Nancy Phelan, Wyethover 18 years ago
Tightening the Chainover 18 years ago
Kurt Graves, Vertexover 18 years ago
Wendy Niebler, Shireover 18 years ago
Perfectly ImperfectAdvertisement
Related to this article
Novo Nordisk reports that CagriSema delivered 12.4% average weight loss in a late-stage diabetes trial, outperforming tirzepatide's 9.1% at comparable doses.
Inovalon's Jen Lamppa on how real-time clinical data feeds validate patient eligibility at enrollment — reducing burden while improving accuracy.
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Lisata Therapeutics acquires Marea Therapeutics and secures $225 million in concurrent financing, while mAbxience and Sandoz partner to develop and globally commercialize an emicizumab biosimilar.
FDA approved Ultragenyx's Fayuvi (rebisufligene etisparvovec-hopf) as the first treatment for MPS IIIA Sanfilippo syndrome type A.
Former Rep. Joe Cunningham (D-SC), now spokesperson for the Pharmaceutical Reform Alliance, argues that codifying Most-Favored-Nation pricing into law is the real fix for drug costs.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.
Advertisement
Advertisement
Trending on PharmExec
1
CagriSema Tops Eli Lilly's Tirzepatide for Weight Loss in Late-Stage Diabetes Trial: Report
2
Understanding the Latest with MFN Pricing and What It Means to Pharma
3
FDA Approves Fayuvi for Pediatric Patients with Sanfilippo Syndrome Type A
4
The Battle to Own the GLP-1 Patient Journey
5